• Rae Staben, Cindy L Vnencak-Jones, Yaping Shi, Matthew S Shotwell, Tarek Absi, Ashish S Shah, Jonathan P Wanderer, Marc Beller, and Miklos D Kertai.
• Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN.
• J. Cardiothorac. Vasc. Anesth. 2023 Oct 1; 37 (10): 197419821974-1982.

ObjectivesTo test the hypothesis that implementation of a cytochrome P-450 2D6 (CYP2D6) genotype-guided perioperative metoprolol administration will reduce the risk of postoperative atrial fibrillation (AF), the authors conducted the Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery pilot study.DesignClinical pilot trial.SettingSingle academic center.ParticipantsSeventy-three cardiac surgery patients.Measurements And Main ResultsPatients were classified as normal, intermediate, poor, or ultrarapid metabolizers after testing for their CYP2D6 genotype. A clinical decision support tool in the electronic health record advised providers on CYP2D6 genotype-guided metoprolol dosing. Using historical data, the Bayesian method was used to compare the incidence of postoperative AF in patients with altered metabolizer status to the reference incidence. A logistic regression analysis was performed to study the association between the metabolizer status and postoperative AF while controlling for the Multicenter Study of Perioperative Ischemia AF Risk Index. Of the 73 patients, 30% (n = 22) developed postoperative AF; 89% (n = 65) were normal metabolizers; 11% (n = 8) were poor/intermediate metabolizers; and there were no ultrarapid metabolizer patients identified. The estimated rate of postoperative AF in patients with altered metabolizer status was 30% (95% CI 8%-60%), compared with the historical reference incidence (27%). In the risk-adjusted analysis, there was insufficient evidence to conclude that modifying metoprolol dosing based on poor/intermediate metabolizer status was associated significantly with the odds of postoperative AF (odds ratio 0.82, 95% CI 0.15-4.55, p = 0.82).ConclusionsA CYP2D6 genotype-guided metoprolol management was not associated with a reduction of postoperative AF after cardiac surgery.Copyright © 2023. Published by Elsevier Inc.

18 keywords...

hide…